09.01.16
CordenPharma said that its Chenôve, France manufacturing facility recently completed an FDA inspection and received a successful response with no 483s reported. The last FDA Inspection took place in 2014.
Yves Michon, managing director, CordenPharma Chenôve, said, “We are pleased with the outcome of the FDA inspection in August 2016, as it reflects our willingness to comply with the highest level of cGMP regulatory compliance while continuously improving our standards for our customers and their projects going forward.”
CordenPharma is a full-service partner in the contract development and manufacturing of APIs, drug products and associated packaging services.
Yves Michon, managing director, CordenPharma Chenôve, said, “We are pleased with the outcome of the FDA inspection in August 2016, as it reflects our willingness to comply with the highest level of cGMP regulatory compliance while continuously improving our standards for our customers and their projects going forward.”
CordenPharma is a full-service partner in the contract development and manufacturing of APIs, drug products and associated packaging services.